Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationTuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationJeffcoate, W. J., & Harding, K. G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13169-8 · Cited by 1,050
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Self-citationColombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Self-citationChemotherapy‐induced neutropenia: Risks, consequences, and new directions for its management
Crawford, J., Dale, D. C., & Lyman, G. H. (2004) · Cancer · doi:10.1002/cncr.11882 · Cited by 882
Cited by
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationLamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
Self-citationKornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Feagan, B. G., Sandborn, W. J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J. R., Blank, M. A., Johanns, J., Gao, L.-L., Miao, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602773 · Cited by 1,845
Self-citationDignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Self-citationGuidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
Sands, B. E., Sandborn, W. J., Panaccione, R., O’Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900750 · Cited by 1,219
Self-citationVan Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Self-citationKirchgesner, J., Lemaitre, M., Carrat, F., Zureik, M., Carbonnel, F., & Dray-Spira, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.012 · Cited by 609
Louis, E., Mary, J., Vernier–Massouille, G., Grimaud, J., Bouhnik, Y., Laharie, D., Dupas, J., Pillant, H., Picon, L., Veyrac, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.034 · Cited by 597
Self-citationKucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Self-citationD'Haens, G. R., Panaccione, R., Higgins, P. D. R., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S. B., Herfarth, H., Hommes, D. W., Kamm, M., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.392 · Cited by 409
Self-citationSaint-Antoine IBD Network, Sokol, H., Landman, C., Seksik, P., Berard, L., Montil, M., Nion-Larmurier, I., Bourrier, A., Le Gall, G., Lalande, V., et al. (2020) · Microbiome · doi:10.1186/s40168-020-0792-5 · Cited by 378
Butyricicoccus pullicaecorum in inflammatory bowel disease
Eeckhaut, V., Machiels, K., Perrier, C., Romero, C., Maes, S., Flahou, B., Steppe, M., Haesebrouck, F., Sas, B., Ducatelle, R., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303611 · Cited by 369
Cottone, M., Kohn, A., Daperno, M., Armuzzi, A., Guidi, L., D'Inca, R., Bossa, F., Angelucci, E., Biancone, L., Gionchetti, P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.026 · Cited by 363
Ford, A. C., & Peyrin-Biroulet, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.138 · Cited by 343
Assessing Response and Loss of Response to Biological Therapies in IBD
Yanai, H., & Hanauer, S. B. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.103 · Cited by 326
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Self-citationInflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets
Biasi, F., Leonarduzzi, G., Oteiza, P. I., & Poli, G. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4530 · Cited by 300
Clinical use of anti-TNF therapy and increased risk of infections
Ali, T., Bronze, Kaitha, Mahmood, Ftaisi, & Stone (2013) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s28801 · Cited by 242
“Immunomodulatory therapy (eg, corticosteroids, methotrexate, azathioprine) and biologic therapy (eg, anti-TNF agents, other monoclonal antibodies), especially when used in combination, are associated with an increased risk of opportunistic infection.(5,9) It must be noted, however, that the risk of opportunistic infec…”
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
SCHNEEWEISS, S., KORZENIK, J., SOLOMON, D. H., CANNING, C., LEE, J., & BRESSLER, B. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04037.x · Cited by 216
Intestinal Microbes in Inflammatory Bowel Diseases
Sartor, R. B., & Mazmanian, S. K. (2012) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2012.4 · Cited by 206
Inflammatory Bowel Disease and the Elderly: A Review
Taleban, S., Colombel, J.-F., Mohler, M. J., & Fain, M. J. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv059 · Cited by 201
Self-citationPeyrin-Biroulet, L., & Lémann, M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04599.x · Cited by 196
“However, the risk-benefit of combination therapy should be assessed in lieu of recent reports of hepatosplenic T-cell lymphomas in young males receiving combination therapy(54) as well as the increased risk of opportunistic infections.(55)”
BackgroundLICHTENSTEIN, G. R., DIAMOND, R. H., WAGNER, C. L., FASANMADE, A. A., OLSON, A. D., MARANO, C. W., JOHANNS, J., LANG, Y., & SANDBORN, W. J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04027.x · Cited by 195
Self-citationAktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014
Preiß, J., Bokemeyer, B., Buhr, H., Dignaß, A., Häuser, W., Hartmann, F., Herrlinger, K., Kaltz, B., Kienle, P., Kruis, W., et al. (2014) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1385199 · Cited by 188
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
Fiorino, G., Peyrin-Biroulet, L., Naccarato, P., Szabò, H., Sociale, O. R., Vetrano, S., Fries, W., Montanelli, A., Repici, A., Malesci, A., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21800 · Cited by 177
“Prolonged and continued pharmacological immunosuppression in patients with IBD can cause some adverse events, particularly the increased risk of opportunistic infections, which can even be fatal.(5) Bacterial, viral, and fungal infections can be potentially dangerous during the course of immunosuppression, and accurat…”
BackgroundTreton, X., Bouhnik, Y., Mary, J., Colombel, J., Duclos, B., Soule, J., Lerebours, E., Cosnes, J., & Lemann, M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.028 · Cited by 168
Self-citationRahier, J., Buche, S., Peyrin–Biroulet, L., Bouhnik, Y., Duclos, B., Louis, E., Papay, P., Allez, M., Cosnes, J., Cortot, A., et al. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.07.022 · Cited by 166
Self-citationYarur, A. J., Kubiliun, M. J., Czul, F., Sussman, D. A., Quintero, M. A., Jain, A., Drake, K. A., Hauenstein, S. I., Lockton, S., Deshpande, A. R., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.12.026 · Cited by 161
Inflammatory Bowel Disease: Crohn’s disease and ulcerative colitis
Wehkamp, J., Götz, M., Herrlinger, K., Steurer, W., & Stange, E. F. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0072 · Cited by 160
Hepatosplenic T cell lymphoma in inflammatory bowel disease: Table 1
Shale, M., Kanfer, E., Panaccione, R., & Ghosh, S. (2008) · Gut · doi:10.1136/gut.2008.163279 · Cited by 159
“Furthermore, the short-term risk of opportunistic infection is significantly increased by such combination therapy.(9)”
BackgroundSystematic review with meta-analysis: inflammatory bowel disease in the elderly
Gisbert, J. P., & Chaparro, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12616 · Cited by 158
Do Not Assume Symptoms Indicate Failure of Anti–Tumor Necrosis Factor Therapy in Crohn's Disease
Bruining, D. H., & Sandborn, W. J. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.019 · Cited by 20
Self-citation
Metadata
- Authors
- Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 134
- Issue
- 4
- Pages
- 929-936
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2131632358
- Cited by
- 1,017
- References
- 31
- FWCI
- 40.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.